🚀 VC round data is live in beta, check it out!
VYNE Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for VYNE Therapeutics and similar public comparables like Curis, Poltreg, Lantern Pharma, Oncoinvent and more.
VYNE Therapeutics Overview
About VYNE Therapeutics
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Founded
2011
HQ
Employees
13
Website
Sectors
Financials (FY)
Market Cap
$21M
VYNE Therapeutics Financials
VYNE Therapeutics reported last fiscal year revenue of $570K and negative EBITDA of ($30M).
In the same fiscal year, VYNE Therapeutics generated ($30M) in EBITDA losses and had net loss of ($26M).
Revenue (LTM)
VYNE Therapeutics P&L
In the most recent fiscal year, VYNE Therapeutics reported revenue of $570K and EBITDA of ($30M).
VYNE Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $570K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($30M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (5215%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (5219%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($26M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (4646%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
VYNE Therapeutics Stock Performance
VYNE Therapeutics has current market cap of $21M.
Market Cap Evolution
VYNE Therapeutics' stock price is $0.62.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $21M | 0.8% | XXX | XXX | XXX | $-0.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVYNE Therapeutics Valuation Multiples
VYNE Therapeutics trades at (33.3x) EV/Revenue multiple, and 0.6x EV/EBITDA.
EV / Revenue (LTM)
VYNE Therapeutics Financial Valuation Multiples
As of April 11, 2026, VYNE Therapeutics has market cap of $21M.
Equity research analysts estimate VYNE Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
VYNE Therapeutics has a P/E ratio of (0.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21M | XXX | $21M | XXX | XXX | XXX |
| EV (current) | ($19M) | XXX | ($19M) | XXX | XXX | XXX |
| EV/Revenue | — | XXX | (33.3x) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 0.6x | XXX | XXX | XXX |
| P/E | — | XXX | (0.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified VYNE Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
VYNE Therapeutics Margins & Growth Rates
VYNE Therapeutics' revenue in the last fiscal year grew by 14%.
VYNE Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.3M for the same period.
VYNE Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (5215%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (32%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1944% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3375% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 5319% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
VYNE Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Curis | XXX | XXX | XXX | XXX | XXX | XXX |
| Poltreg | XXX | XXX | XXX | XXX | XXX | XXX |
| Lantern Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncoinvent | XXX | XXX | XXX | XXX | XXX | XXX |
| Biotechnology Assets | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
VYNE Therapeutics M&A Activity
VYNE Therapeutics acquired XXX companies to date.
Last acquisition by VYNE Therapeutics was on XXXXXXXX, XXXXX. VYNE Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by VYNE Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVYNE Therapeutics Investment Activity
VYNE Therapeutics invested in XXX companies to date.
VYNE Therapeutics made its latest investment on XXXXXXXX, XXXXX. VYNE Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by VYNE Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout VYNE Therapeutics
| When was VYNE Therapeutics founded? | VYNE Therapeutics was founded in 2011. |
| Where is VYNE Therapeutics headquartered? | VYNE Therapeutics is headquartered in United States. |
| How many employees does VYNE Therapeutics have? | As of today, VYNE Therapeutics has over 13 employees. |
| Who is the CEO of VYNE Therapeutics? | VYNE Therapeutics' CEO is David Domzalski. |
| Is VYNE Therapeutics publicly listed? | Yes, VYNE Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of VYNE Therapeutics? | VYNE Therapeutics trades under VYNE ticker. |
| When did VYNE Therapeutics go public? | VYNE Therapeutics went public in 2018. |
| Who are competitors of VYNE Therapeutics? | VYNE Therapeutics main competitors are Curis, Poltreg, Lantern Pharma, Oncoinvent. |
| What is the current market cap of VYNE Therapeutics? | VYNE Therapeutics' current market cap is $21M. |
| What is the current revenue of VYNE Therapeutics? | VYNE Therapeutics' last fiscal year revenue is $570K. |
| What is the current EV/Revenue multiple of VYNE Therapeutics? | Current revenue multiple of VYNE Therapeutics is (33.3x). |
| Is VYNE Therapeutics profitable? | No, VYNE Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.